Article Per Year (5 Year)
p-Index From 2020 - 2025
1.452
P-Index
This Author published in this journals
All Journal Indonesian Journal of Cancer Chemoprevention Medica Hospitalia Indonesian Journal of Global Health research Narra J Indonesian Journal of Cancer
Catharina Suharti
Department of Internal Medicine, School of Medicine, Diponegoro University and Dr. Kariadi Hospital, Semarang, Indonesia, Jl. Dr. Sutomo 18 Semarang
Biochemistry, Genetics & Molecular Biology Dentistry Education Health Professions Immunology & microbiology Languange, Linguistic, Communication & Media Medicine & Pharmacology Nursing Public Health

Published : 7 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 7 Documents
Search

 1 
Synergistic Cytotoxicity of 5-Fluorouracil and Epigallocatechin-3-Gallate on Colorectal Cancer Stem Cell Ibrahim, Sugeng; Riwanto, Ignatius; Suharti, Catharina; Putra, Agung; Budijitno, Selamat
Indonesian Journal of Cancer Vol 18, No 2 (2024): June
Publisher : http://dharmais.co.id/

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v18i2.1211

Abstract

Background: Colorectal cancer stem cells (CR-CSCs) derived from the HCT-116 cell line established human colon carcinoma cell line, validated with CD44+/CD133+. The study investigates the synergistic effects of combining epigallocatechin gallate (EGCG) with 5-fluorouracil (5-FU) on CR-CSCs through comprehensive cytotoxicity assessments, aiming to enhance therapeutic outcomes. EGCG is a polyphenol with anti-cancer activity in green tea. Previous studies have reported that the anti-cancer activity of EGCG involves inhibition of proliferation and induction of apoptosis thereby reducing recurrence by as much as 51.6% in patients with colorectal adenoma after polypectomy. The significance lies in optimizing treatment strategies by understanding the potential synergies between conventional chemotherapeutic agents and natural compounds. Given 5-FU's status as a cornerstone in CR-CSCs chemotherapy and EGCG's emergence as a promising natural compound, the study delves into their individual and combined cytotoxicity profiles. Methods: The single and combination assay aimed to determine the cytotoxicity of EGCG and 5-FU, including establishing the half inhibitory concentration (IC50) and combination index (CI) values. CR-CSCs colonies were disassociated, counted, and cultured in 96-well plates. Test solutions of varying concentrations were applied, and subsequent steps involved incubation, media removal, washing, MTT reagent addition, and absorbance measurement. Results: The single cytotoxicity tests established individual IC50 values, revealing 141.26 µM for 5-FU and 464.56 µM for EGCG. Subsequent combination cytotoxicity tests demonstrated a synergistic effect at specific doses, indicated by CI values below 1. Conclusions: These findings highlight the potential for increased cytotoxicity against CR-CSCs when treated with the combination of 5-FU and EGCG.
Curcumin for Quality of Life of Multiple Myeloma Patients: a Randomized, Placebo-Controlled Trial: Curcumin for Quality of Life of Multiple Myeloma Patients: a Randomized, Placebo-Controlled Trial Hendrawati, Anindita Rosenda Eka; Santosa, Damai; Dharminto, Dharminto; Suharti, Catharina
Medica Hospitalia : Journal of Clinical Medicine Vol. 9 No. 2 (2022): Med Hosp
Publisher : RSUP Dr. Kariadi

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (292.578 KB) | DOI: 10.36408/mhjcm.v9i2.757

Abstract

Background : The main goal of multiple myeloma (MM) therapy is to control the disease, prolong the survival, and improve the life quality. Curcumin affects pro-inflammatory cytokines. There is no research yet that has been conducted to evaluate the effects of curcumin on increasing MM patient's life quality. Objective of this study is to evaluate the effect of curcumin on increasing MM patients' life quality. Methods : Of 24 MM patients were enrolled and were divided randomly into treatment groups (n=12) and controls (n=12). Patients in treatment group received melphalan 4 mg/m2, prednisone 40 mg/m2 (MP) for 7 days and curcumin 8 grams/day for 28 days. The control group received MP and placebo. Quality of life (QoL) scores were measured in early diagnosis and after 4 cycles of treatment. The difference between two groups was analyzed using Mann-Whitney U-Test or Independent T Test. Results : The role function score of the treatment group was better than control. There is a significant difference function score of patients between the treatment and control group, at baseline and 4 cycles treatment (41.66 ± 3.85 vs. 23.61 ± 3.36; 95.83 ± 1.03 vs 76.39 ± 2.51; p=0.022). There was significantly different of insomnia score between treatment and control goup at baseline and the end 4 cycles (41.67 ± 3.79 vs 58.33 ± 3.51; 9.72 ± 1.5 vs 25 ± 1.32; p=0.02). Conclusion : The addition of curcumin in myeloma patients enhances the QoL score, role function score and lowered symptom insomnia.
Nilai Rerata Volume Trombosit, Rasio Trombosit Limfosit, Rasio Rerata Volume Trombosit-Limfosit sebagai Prediktor Tingkat Keparahan Sindrom Koroner Kronik Wijaya, Friska; Limantoro, Charles; Fitria, Indah; Suharti, Catharina; Nugroho, Trilaksana
Medica Hospitalia : Journal of Clinical Medicine Vol. 10 No. 1 (2023): Med Hosp
Publisher : RSUP Dr. Kariadi

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36408/mhjcm.v10i1.813

Abstract

BACKGROUND: The increase in platelet aggregation and inflammation play an essential role in atherosclerosis. Furthermore, the level of activity depends on their size, with larger platelets facilitating the thrombosis process. Severe Coronary Artery Disease (CAD) is associated with low lymphocyte count. It is also linked with Mean platelet volume [MPV], Platelet Lymphocyte Ratio [PLR], and Mean Platelet Volume to Lymphocyte Ratio [MPVLR]. OBJECTIVE:  This study aims to investigate MPV, PLR, and MPVLR as predictors of the severity of Coronary Artery Lesion in Chronic Coronary Syndrome (CCS) using the Gensini score. METHOD: This is a cross sectional study conducted in Dr. Kariadi General Hospital, involving a total sample of 68 respondents. Furthermore, CCS were evaluated before conducting coronary angiography. The study comprises of two group of patients divided according to their Gensini scores, namely mild and severe, for ≤ 20 and > 20, respectively. MPV, PLR, and MPVLR were then compared between the two groups. RESULT: At a cut-off level of 3.4, MPVLR predicted the coronary artery severity with a sensitivity, specificity, positive predictive value (PPV), and negative predictive value of 80%, 50%, 82%, and 47% (area under the curve [AUC] 0.67; 95% confidence interval [CI], 0.52-0.82; p 0.029). Meanwhile, its value ≥3.4 has OR 1.55; 95% CI, 0.99-2.43; p 0.034. CONCLUSION: This study conclude that MPVLR ≥3.4 can be used as a predictor of Coronary Artery Lesion Severity based on the Gensini score in CCS cases.
Predictors for 30-day mortality in hepatocellular carcinoma patients undergoing liver resection Prabowo, Erik; Susilaningsih, Neni; Suharti, Catharina; Purnomo, Hery D.; Riwanto, Ignatius; Fuadi, Ahmad F.; Ar, Ardiyana; Bulandari, Beatrice LA.; Tjandra, Kevin C.; Respati, Danendra RK.; Rampengan, Derren DCH.
Narra J Vol. 4 No. 3 (2024): December 2024
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v4i3.1001

Abstract

Hepatocellular carcinoma (HCC) ranks among the most prevalent and fatal liver cancers globally. Liver surgery, particularly resection, offers the potential for cure but poses challenges, especially in Indonesia, where patients often present in advanced stages. This study aimed to determine the intraoperative and perioperative factors associated with 30-day mortality of HCC patients undergoing liver resection at a tertiary referral hospital. The study included HCC patients undergoing liver resection at Karadi General Hospital, Semarang, Indonesia, between January 2018 and September 2023. Demographic data, intraoperative, perioperative, and postoperative factors were collected, with the primary outcome being 30-day mortality. Factors influencing 30-day survival were assessed using a log-rank test and the survival analysis employed Kaplan-Meier curves. Among 58 HCC patients who had liver resection, 62.1% were males, with a mean age was 57.27±9.56 years old. Preoperative comorbidities, notably hepatitis B, affected 34.4% of patients. Child-Pugh Score categorized 91.4% as class A. The study found a 30-day mortality rate of 10.3% with no subsequent increase in incidence. The failure-to-rescue rate (FTR) of this study was found to be 46%. Factors associated with 30-day mortality were Child-Pugh classification (p<0.001), intraoperative bleeding (p=0.001), creatinine levels (p=0.005), Clavien-Dindo classification (p<0.001), and posthepatectomy liver failure (PHLF) (p<0.001). This study suggests that pre-operative (Child-Pugh classification), intraoperative (blood loss volume) and postoperative factors (Creatinine level, Clavien-Dindo classification, and PHLF) could predict the mortality rate of HCC patients undergoing liver resection.
The Efficacy and Safety of Ixazomib for Newly Diagnosed Multiple Myeloma (NDMM) and Refractory or Relapsed Multiple Myeloma (RRMM): An Updated Systematic Review Lubis, Ainun Basyiroh; Santosa, Damai; Rizky, Daniel; Tandarto, Kevin; Kartiyani, Ika; Yunarvika, Vina; Ardini, Desta Nur Ewika; Setiawan, Budi; Pangarsa, Eko Adhi; Suharti, Catharina
Indonesian Journal of Cancer Vol 19, No 2 (2025): June
Publisher : http://dharmais.co.id/

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v19i2.1241

Abstract

Background: Newly diagnosed multiple myeloma (NDMM) is a significant healthcare concern, comprising 1.8% of newly diagnosed cancers in the United States. Recent advancements in NDMM and refractory/relapsed multiple myeloma (RRMM) treatment, including novel agents like ixazomib, have improved patient outcomes. Ixazomib, an oral proteasome inhibitor, has shown promise in clinical trials, particularly in combination with lenalidomide and dexamethasone (IRd). This study aims to find the efficacy and safety profiles of ixazomib for NRMM and RRMM.Methods: We conducted a systematic literature review using Scopus, PubMed, Google Scholar, and ProQuest databases, focusing on randomized controlled trials (RCTs) evaluating ixazomib’s efficacy and safety in NDMM and RRMM treatment. Eligibility criteria included studies published within the last 3 years reporting data on ixazomib in NDMM and RRMM patients. Quality assessment utilized the Cochrane Risk of Bias tool for RCTs.Results: The review identified three studies from 2021–2023 demonstrating ixazomib’s efficacy and safety in MM treatment across various patient groups. Benefits included improved progression-free survival (PFS) in non-transplant NDMM, significant PFS advantage in relapsed/ refractory MM, and efficacy in transplant-ineligible NDMM induction regimens.Conclusion: Ixazomib emerges as a well-tolerated maintenance therapy offering significant PFS advantages in NDMM and RRMM, irrespective of age or frailty status. Future research, including multicenter studies, is warranted to further elucidate ixazomib’s role in MM management.
Adherence to Guidelines: Evaluation of Opioid Usage According to the Who Step Ladder Guideline in Inpatient Cancer Patients Pangarsa, Eko Adhi; Setiawan, Budi; Santosa, Damai; Rizky, Daniel; Yunarvika, Vina; Suharti, Catharina
Indonesian Journal of Global Health Research Vol 7 No 4 (2025): Indonesian Journal of Global Health Research
Publisher : GLOBAL HEALTH SCIENCE GROUP

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37287/ijghr.v7i4.6343

Abstract

WHO analgesic step-ladder is still the mainstay guideline in managing pain. However, pain in cancer patients developed from a more complex pathomechanism, hence requiring special consideration. This study aimed to compare the visual analog scale (VAS) of opioid and non-opioid analgesia in treating cancer patients and evaluate its rationality with World health organization (WHO) analgesic step-ladder.Method: A single-center, cross-sectional and analytic-descriptive study conducted in our centre. The population of this study comprised all cancer patients receiving analgesic therapy. The sampling technique used was consecutive, involving patients who met the inclusion and exclusion criteria. A total of 62 patients were included in the study as the research sample. Pain level was measured before and between 12 – 24 hours after analgesia, using VAS and divided into mild, moderate, or severe. Analgesic regimens were documented, and the daily opioid dose was presented on milligram morphine equivalent. Statistical analysis was performed to compare the variables before and after analgesia using the Wilcoxon signed-rank test, with a p-value <0.05 considered statistically significant.Result: From 62 patients, 46 subjects were included. Median milligram morphine equivalent was 20 mg (0-60). While the majority of patients experienced mild pain, 13 patients (27.7%) had moderate to severe pain. The most commonly used opioid was intravenous fentanyl, administered to 13 patients (27.7%), with a median morphine equivalent dose of 20 mg/day. Only 1 patient received opioid rationally according to WHO. Both non-opioid and opioid group had significant VAS differences before and after therapy (p = 0.014 and p <0.001). In both non-opioid and opioid groups, there were differences of VAS scores in the post-administration of analgesic, but these differences were not statistically significant (p= 0.885). Conclusion: The study concludes that, although most analgesics were not administered in accordance with the WHO step-ladder guideline, both opioid and non-opioid analgesics were effective in reducing pain in palliative cancer patients.
Addition of Beetroot Extract to Neoadjuvant Adriamycin Cyclophosphamide Regimen Increased Tumor Cell Apoptosis in Mammary Adenocarcinoma Rats Susilowati, Sri; Susilaningsih, Neni; Suharti, Catharina
Indonesian Journal of Cancer Chemoprevention Vol 12, No 3 (2021)
Publisher : Indonesian Society for Cancer Chemoprevention

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.14499/indonesianjcanchemoprev12iss3pp130-136

Abstract

Apoptosis is one of the anticancer targets. Currently, the concomitant use of phytotherapy products and chemotherapy regimens is common in breast cancer patients. The purpose of this study was to examine the apoptotic effect of adding beetroot extract to the neoadjuvant Adriamycin Cyclophosphamide (AC) regimen by observing the expression levels of p53 and caspase 3 in tumor tissue from mammary adenocarcinoma rats. Twenty-four rats that succeeded in growing tumor nodules were randomly divided into 4 treatment groups: without treatment, AC only treatment, AC plus beetroot extract at dose of 25 and 100 mg/kg BW, respectively. AC was given 4 cycles in doses of 5 and 50 mg/kg body weight intraperitoneally every week. Tumor tissue was dissected at 4th week for examination of p53 and caspase 3 expression levels using the qRT-PCR method. The addition of beetroot extract at doses of 25 and 100 mg/kg BW in the neoadjuvant AC regimen showed significantly higher levels of p53 and caspase 3 expression than those with AC treatment alone. These results proved that beetroot extract has a synergistic effect with neoadjuvant AC regimen by increasing tumor cells apoptosis.Keywords: Beetroot extract, Adriamycin, Cyclophosphamide, apoptosis, p53.
Co-Authors Agung Putra Ar, Ardiyana Ardini, Desta Nur Ewika Budi Setiawan Bulandari, Beatrice LA. Charles Limantoro Damai Santosa Dharminto Dharminto Fuadi, Ahmad F. Hendrawati, Anindita Rosenda Eka Ibrahim, Sugeng Ignatius Riwanto, Ignatius Indah Fitria, Indah Kartiyani, Ika Lubis, Ainun Basyiroh Neni Susilaningsih Nugroho, Trilaksana Pangarsa, Eko Adhi Prabowo, Erik Purnomo, Hery D. Rampengan, Derren DCH. Respati, Danendra RK. Rizky, Daniel Santosa, Damai Selamat Budijitno Sri Susilowati Tandarto, Kevin Tjandra, Kevin C. Wijaya, Friska Yunarvika, Vina